NEW ORLEANS–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, announced today that its products will be featured in numerous presentations at the annual American Society of Cataract and Refractive Surgery (ASCRS) meeting being held at the Ernest N. Morial Convention Center in New Orleans, LA on May 6-10, 2016. “The A
ALPHARETTA, Ga.–(BUSINESS WIRE)–Clearside Biomedical, Inc. to present four posters associated with suprachoroidal drug administration at the May 1-5, 2016 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Gene therapy for choroideremia continues to improve some patients’ vision 3.5 years after treatment. Medscape Medical News
Repeat Descemet’s stripping automated endothelial keratoplasty produced endothelial cell loss rates and visual acuity results comparable to those of a primary procedure, according to one study.The retrospective paired comparison included 51 eyes that underwent one or more DSAEK procedures following primary DSAEK between January 2005 and June 2015 at Villa Serena-Villa Igea Private Hospitals in Forli, Italy. Primary and secondary results of DSAEK surgeries were compared.
Retreatment with ranibizumab is necessary for up to a third of neovascular age-related macular degeneration (AMD) patients who are treatment-free for one year, new research shows. Reuters Health Information
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has completed …